CP-135 Treatment of pneumonia in geriatric patients. (24th February 2014)

• Record Type: Journal Article
• Authors: Selvi-Sabater, P; Rizo-Cerda, AM; Sanchez-Martinez, I; Manresa-Ramon, N; Arribas-Diaz, B; Morego-Soler, A; Boso-Ribelles, A; Sanchez-Mulero, MC; Titos-Arcos, JC; Sanchez-Catalicio, MM
• Is Part Of: European journal of hospital pharmacy. Volume 21(2014)Supplement 1
• Page Start: A54
• Page End: A55
• Publication Date: 2014-02-24
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2013-000436.133
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background: Pneumonia is one of the most common causes of mortality in geriatric patients. The appropriate antibiotic treatment of this pathology can decreases the mortality rate in the patient group. Purpose: To study the features of the patients with community acquired pneumonia (CAP) and the use of antibiotics in their treatment. Materials and methods: We selected 102 hospitalised patients who met the CAP criteria. Demographics, stay, comorbidities, smoking/drinking habits, microbiological tests performed and empirical antibiotic treatment were collected. Finally, we compared the treatment we found with clinical practice guidelines. Results: Of the 102 patients selected (58.8% men and 41.2% woman) 75 (73.5%) of patients were over 65, and the median age was 70. The average stay was 8.6 days. The most frequent comorbidities in patients with CAP were diabetes in 31 patients (30.4%) and onco-haematology disease in 26 patients (25.5%) follow by respiratory disease in 22 patients (21.6%). The most common empirical treatments were fluoroquinolone monotherapy (36.27%) and fluoroquinolone associated with B-lactam (38.25%). Finally 14 (87.5%) of the 16 who died had at least one comorbidity, and 5 (31.25%) had at least three comorbidities. Conclusions: Patients with CAP included in the study were treated in accordance with clinical guidelines. In patients with comorbidities there is a greater risk of dying. No conflict of interest.